CoChat

Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments

Simon, Neal, Guillon, Christophe, Fabio, Karine, Heindel, Ned, Lu, Shi-fang, Miller, Marvin, Ferris, Craig, Brownstein, Michael, Garripa, Carrie, Koppel, Gary · 2008 · Recent Patents on CNS Drug Discovery
Cited by 51

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

A compelling case for the potential utility of vasopressin (AVP) antagonists as a novel therapeutic class for the treatment of stress-related affective illness has emerged based on observations in depressed individuals, findings in animal models of anxiety and depression, and an understanding of changes in hypothalamic-pituitary-adrenal (HPA) axis regulation under chronic stress. The scientific bases for vasopressin antagonists as a pharmacotherapy for anxiety and depression include: 1) the neuroadaptation and dysregulation of HPA function that accompanies chronic stress in affected humans and in animal models of anxiety and depression, 2) recognition that AVP, not corticotrophin releasing factor (CRF), drives HPA function associated with chronic psychological stress, 3) the CNS localization of vasopressin V1a and V1b receptors in limbic system regions involved in HPA regulation and control of social behaviors, and 4) preclinical data showing efficacy in animal models employed as screens for anxiolytic and antidepressant activity. The public health need for new pharmaceutical treatments for stress-related affective illness is well documented. In the United States alone, anxiety and depression affect some 40 million people each year and carry a conservatively estimated annual total economic burden of at least $125 billion. Existing pharmacotherapies for both indications are not uniformly effective and frequently have undesirable side effects. These limitations demonstrate that a new treatment approach through vasopressin receptor antagonism in the CNS may offer significant opportunities for improved outcomes. In this review, the development of compounds in this class since 2005 is considered. The most advanced clinical candidates and newer compounds described in recent patents are presented.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/157488908784534586

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 51

Metadata

Authors
Simon, N., Guillon, C., Fabio, K., Heindel, N., Lu, S.-F., Miller, M., Ferris, C., Brownstein, M., Garripa, C., & Koppel, G.
Venue
Recent Patents on CNS Drug Discovery
Published
2008-06-01
Volume
3
Issue
2
Pages
77-93
ISSN
1574-8898 (ISSN-L)
OpenAlex
W2144839731
Cited by
51
References
14
FWCI
1.77
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments. https://app.cochat.ai/papers/10.2174/157488908784534586
The paper
Simon, N., Guillon, C., Fabio, K., Heindel, N., Lu, S.-F., Miller, M., Ferris, C., Brownstein, M., Garripa, C., & Koppel, G. (2008). Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments. Recent Patents on CNS Drug Discovery. https://doi.org/10.2174/157488908784534586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.